US Stock Market Move | HUTCHMED (HCM.US) rises more than 5% as results of SACHI III trial published in The Lancet.

On Friday, HUTCHMED (HCM.US) rose over 5%, reaching $16.12. On the news front, HUTCHMED announced that the results of the SACHI Phase III study have been published in "The Lancet". SACHI is a combination therapy of savolitinib and osimertinib used for the treatment of locally advanced or metastatic non-small cell lung cancer patients with EGFR mutation-positive disease progression after receiving first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and MET gene amplification. Savolitinib is a potent, highly selective oral MET TKI jointly developed by Astrazeneca PLC Sponsored ADR and HUTCHMED, and commercialized by Astrazeneca PLC Sponsored ADR. Osimertinib is an irreversible third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.